Nichole Tucker


Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis

April 11th 2021

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

Maintenance Niraparib Maintains PFS Improvement in gBRCA+/- Ovarian Cancer

March 22nd 2021

Maintenance niraparib demonstrated clinical benefit that persisted beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.  

Ruxolitinib Showcases Early Efficacy, Safety in Pediatric Chronic GVHD

February 9th 2021

February 9, 2021 - Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.

Repotrectinib Elicits Early Responses in ROS1+ Metastatic NSCLC

January 31st 2021

January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.

Anlotinib Induces PFS Benefit in RAS/BRAF Wildtype+ mCRC

January 15th 2021

January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.

Ki-67 Can Be Used to Select Abemaciclib for Patients With High-Risk Early Breast Cancer

December 10th 2020

December 10, 2020 - Treatment with abemaciclib in combination with endocrine therapy significantly reduced the risk of invasive disease recurrence or death in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who had high Ki-67 tumors, suggesting that this feature can be used in conjunction with high-risk features to select patients for abemaciclib in the adjuvant setting.

Brentuximab Vedotin Shows Encouraging Responses Rates, Tolerability in Older Patients With Hodgkin Lymphoma

December 8th 2020

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

Ponatinib Elicits High Responses, Robust Outcomes in CP-CML Following TKI Failure

December 8th 2020

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

CD47-Directed TTI-622 Elicits Early Efficacy Signals in Relapsed/Refractory Lymphoma

December 6th 2020

December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.

Early Allogeneic HSCT With HLA-Matched Donor Improves Outcomes in Older Patients With Higher-Risk MDS

December 6th 2020

December 6, 2020 - Having a human leukocyte antigen–matching donor for allogeneic hematopoietic stem cell transplant has proven to lead to improved outcomes for patients who are between 50 and 75 years of age and have higher-risk myelodysplastic syndrome.